These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33213976)

  • 1. The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial.
    Zendehdel A; Ansari M; Khatami F; Mansoursamaei S; Dialameh H
    Clin Nutr; 2021 May; 40(5):3325-3331. PubMed ID: 33213976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.
    Sengupta G; Hazra A; Kundu A; Ghosh A
    Clin Ther; 2011 Dec; 33(12):1943-52. PubMed ID: 22177370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study.
    Detering M; Steels E; Koyyalamudi SR; Allifranchini E; Bocchietto E; Vitetta L
    Biofactors; 2017 Nov; 43(6):789-800. PubMed ID: 29048765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D Deficiency as a Potential Marker of Benign Prostatic Hyperplasia.
    Zhang W; Zheng X; Wang Y; Xiao H
    Urology; 2016 Nov; 97():212-218. PubMed ID: 27327576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamsulosin efficiency in treatment of benign prostatic hyperplasia evaluated by determining bladder weight.
    Milicevic S
    Med Arch; 2012; 66(6):391-5. PubMed ID: 23409519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations of glucose metabolism, insulin resistance and inflammatory factors with symptom score of patients with benign prostatic hyperplasia.
    Zhou B; Wang P; Xu WJ; Li YM; Tong DL; Jiang J; Sun ZY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(16):5077-5081. PubMed ID: 30178825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
    Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
    Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
    Colli E; Rigatti P; Montorsi F; Artibani W; Petta S; Mondaini N; Scarpa R; Usai P; Olivieri L; Maggi M;
    Eur Urol; 2006 Jan; 49(1):82-6. PubMed ID: 16310924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
    Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
    Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
    Wang JY; Fu YY; Kang DY
    Medicine (Baltimore); 2016 May; 95(19):e3243. PubMed ID: 27175628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lycopene inhibits disease progression in patients with benign prostate hyperplasia.
    Schwarz S; Obermüller-Jevic UC; Hellmis E; Koch W; Jacobi G; Biesalski HK
    J Nutr; 2008 Jan; 138(1):49-53. PubMed ID: 18156403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?
    Schenk JM; Hunter-Merrill R; Zheng Y; Etzioni R; Gulati R; Tangen C; Thompson IM; Kristal AR
    Am J Epidemiol; 2013 Sep; 178(5):741-51. PubMed ID: 23813705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.